Kugako Sugimoto, NOST Tokyo
Origineel gepubliceerd op de site van Agentschap NL
Samenvatting
De BioJapan in oktober 2014 in Yokohama is één van de grootste evenementen waar experts uit de biotech industrie jaarlijks bijeenkomen. De Nederlandse ambassade is van plan hier een stand op te zetten voor het Holland Bio Cluster en moedigt Nederlandse bedrijven aan om hieraan mee te doen. De BioJapan 2014 maakt gebruik van een computersysteem dat de match making organiseert tussen de aanwezige bedrijven. Er zijn dus veel mogelijkheden zom bedrijven te ontmoeten. Verder is de ambassade van plan parallelle bijeenkomsten te organiseren met het Holland Bio Cluster.
Bio Japan 2014 and the Holland Bio Cluster
Summary
Bio Japan 2014, one of the largest events to meet professionals in the biotech industry, will be held in October in Yokohama, Japan. The Netherlands Embassy in Japan will set up abooth for the Holland Bio Cluster at Bio Japan 2014 and encourages Dutch companies to join us. A computer based match-making system of Bio Japan 2014 will provide opportunities for meetings with the companies you are interested in. Side events with the Holland Bio Cluster at the Embassy are also planned.
Details
Bio Japan is an event to meet professionals in the field of the biotech industry. It will be held on October 15-17, 2014 in Yokohama, Japan. In 2013, 607 groups participated in the match making service and 4747 meetings were held during the last year’s event. A participant usually meets with more than one partnering candidate. 34.2% and 16.3% of partnering event participants were in the field of drug/drug discovery and research institute/universities respectively. Other participants were from CRO/CMO, government office/bio-related associations, chemical/food/cosmetics, medical treatment/diagnosis devices, and environment/energy. Participants came from European countries (57.9%), North America (17.2%), and Asia/Oceania (24.9%). Agendas of the meetings focused on business collaboration for joint research/development (27.3%), in-licensing of product/technology (20%), out-licensing of product/technology (19.4%), buying/consideration of product/service (10%), and selling/suggestion of product/service (14.4%).
Seminars on diverse subjects were held, such as environmental issues including biofuel (algae), medical, healthcare, pharmaceutical (iPS cells research, personalized medicine, medical equipment, informatics, cohort studies), food/agriculture/aquaculture (functional food, plant factories), and biotech industry (e.g. bio-venture). This year, Novel Prize Laureate, Professor Shinya Yamanaka will give a seminar about iPS cells research.
Japanese Bio Industry
The present Japanese government expects the biotech industry to boost up Japanese economy according to the economic plan called Abenomics, named after the current Prime Minister. Concrete measures for lifesicence in this plan include a Japanese-version of the US National Institutes of Health to coordinate research on a nationwide scale, expanded advanced medical care, selling non-prescription drugs through internet, and IT use for medical treatment, home care, and medication. Relaxation of regulations is one type of measures such as selling drugs on Internet. Another is top-down initiative such as the establishment of a Japanese NIH. The Japanese NIH would choosecompetitive lifesicence areas and allocate ample research funds, people, and facilities on selected subjects. Probably, iPS cells research will be the most focused research area in lifescience. One of the key research institutes of iPS cells is the Center for iPS Cell Research and Application (CiRA) of Kyoto University, where Professor Shinya Yamanaka serves as a head. Recently, the institute published papers about the effective creation of iPS cells to alleviate Parkinson’s disease, which would probably be the second clinical trial using iPS cells in Japan. Another research team of CiRA succeeded in the production of large amounts of megakaryocyte* to produce blood platelets in order to stop bleeding. Another leading institute is RIKEN where the world first clinical research to treat age-related macular degeneration** by using iPS cells is currently conducted. Research on iPS cells is very active in Japan.
If you are interested in expanding your business network, exploring business opportunities in Japan, please feel free to contact the Embassy of the Netherlands in Japan to discuss joining the Holland Bio Cluster, side events such as pre-event briefing at the Embassy, and sharing the booth and time for on-site presentation with us (mail@nost.jp).
* megakaryocyte (Wikipedia)
** age-related macular degeneration (Wikipedia)
Source
2. CiRA
3. RIKEN
